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Introduction
The Beckwith-Wiedemann syndrome (BWS) (MIM 130650) is characterized by a wide variety of growth abnormalities. Exomphalos, macroglossia, and gigantism-which are the most common features-are variably present and can be found in association with multiple anomalies such as hypoglycemia, ear pits and creases, and hemihypertrophy (Pettenati et al. 1986 ). BWS patients are prone to develop several embryonic tumors (7.5%), most commonly (40% of all tumors) Wilms tumor (WT) (MIM 194071) (Wiedemann 1983 ). Both linkage studies and the presence of chromosomal abnormalities assigned this syndrome to chromosome 11p15.5 (Koufos et al. 1989; Ping et al. 1989 ), containing, amongst others, the gene IGF2.
The molecular etiology of BWS is complex and involves genomic imprinting (Mannens et al. 1994) . Only recently has it been possible to develop a hypothesis to explain some of its features. It is suggested that inheritance of two functional copies of the primarily paternally expressed IGF2 gene results in overproduction of this fetal-growth factor and consequent changes to development of predominantly mesodermally derived tissues and organs. Evidence for this hypothesis comes from the observation of parent-of-origin effects in BWS where the disorder is sometimes associated with inher-itance of two copies of IGF2 via the paternal germline (paternal UPD and partial trisomies) (Weksberg et al. 1996 and references therein) and the observation that the majority of BWS patients show loss of imprinting of this gene (Weksberg et al. 1993; Reik et al. 1995; Brown et al. 1996; Joyce et al. 1997 ). More direct evidence for a role for IGF2 in BWS comes from the phenotype of mice overexpressing or transgenic for Igf2, which exhibit BWS-like morphological changes (Sun et al. 1997; Eggenschwiler et al 1997) .
A cluster of translocation breakpoints, contained within an ∼300-kb interval 200-300 Kb proximal of IGF2, defines the BWS chromosome region 1 (BWSCR1) . BWSCR1 is in the center of a region that contains multiple imprinted genes including IGF2, H19, CDKN1C (also known as p57 KIP2 ), ASCL2 (also known as HASH2), and KCNQ1 (also known as KVLQT1). All breakpoints in BWSCR1 disrupt the imprinted (maternally expressed) KCNQ1 gene (Lee et al. 1997b ). The involvement of KCNQ1 in BWS and the effect of the translocations in this region on the imprinting and expression of the other candidate genes are not yet fully understood. In any event, in at least two patients, disruption of BWSCR1 results in loss of imprinting (LOI) of IGF2 (Brown et al. 1996; Smilinich et al. 1999) .
Several observations suggest that disruption of IGF2 imprinting is not the only process involved in the etiology of BWS. Recently, LIT1, an imprinted transcript antisense to KCNQ1, was identified. LOI of this paternally expressed transcript is observed in ∼50% of the BWS patients and seems to be independent of LOI of IGF2. In addition, mutations in the preferentially maternally transcribed cell-cycle inhibitor CDKN1C, are found in a small subset of patients (Hatada et al. 1996; Okeefe et al. 1997; Lee et al. 1997a; authors' unpublished data) and the phenotype of mice null for cdkn1c had some similarities to BWS (Zhang et al. 1997; Yan et al. 1997) . The exact molecular events associated with BWSCR1 rearrangements and BWS remain to be established, but two additional regions of rearrangements add further complexity.
BWSCR2 and BWSCR3 map, respectively, 5 Mb and 7 Mb more proximal to BWSCR1 . BWSCR2 is defined by two breakpoints and may be associated with a distinct phenotype. Patient WH5.1 has hemihypertrophy and ear pits and grooves and has developed a Wilms tumor. Patient CRO2 presented with gigantism, cardiac abnormalities (dextrocardia, cardiomegaly, and septum defects), and hemihypertrophy and underwent hypoglycemic crisis. Thus, both patients have only minor BWS features-but both have hemihypertrophy, a feature not seen in patients with chromosomal breakpoints in BWSCR1 and BWSCR3. Hemihypertrophy is associated with an increased risk for childhood tumors. It is frequently present in BWS patients with Wilms tumors (40%, compared with 12.5% in BWS patients without Wilms tumors) (Wiedemann 1983) . DeBaun et al. (1998) suggest a 4.6-fold increased relative risk in such patients. Patient WH5.1 did indeed develop a Wilms tumor. As such, WH5.1 is the only BWS/hemihypertrophy patient carrying a balanced translocation that developed a childhood tumor.
The distance between the regions, the fact that they do not disrupt the same large imprinted region, and the phenotypic heterogeneity between the patients with breakpoints in the different regions make it seem unlikely that cis-acting DNA sequences are affected by BWSCR2/3. We would suggest that an alternative hypothesis could be that there is a gene(s) at BWSCR2 and BWSCR3 that interacts with some components of the IGF2/BWSCR1 system and influences the BWS phenotype via this mechanism.
In this article, we describe the isolation of two zincfinger genes at BWSCR2: ZNF214 and ZNF215. Alternative splice variants of ZNF215, partially running antisense of ZNF214, are disrupted by the breakpoints. ZNF215 is expressed preferentially from the maternal allele, whereas ZNF214 is not imprinted. These data support a role for ZNF215, and possibly for ZNF214, in the etiology of BWS.
Material and Methods

Patient Material
Genomic DNA and high-resolution metaphase chromosomes were isolated from Epstein-Barr virus-transformed lymphoblastoid cell lines of pa-tients WH5.1 (inv[11][p15.4;q22.2] ) and CRO2 (t[10; 11][p13; p15.4] ).
Fluorescent In Situ Hybridization
Cosmids and YACs were labeled by nick-translation. Hybridization was performed on metaphase chromosomes, as described previously (Hoovers et al. 1992 ). Hybridization to linear DNA was performed according to Fidlerova et al. (1994) .
Construction of a Cosmid Contig
YAC A39D9 was subcloned in cosmid vector Lawrist 4. All cosmids were fingerprinted to identify potential overlap with each other and other cosmids in a database to construct a contig, as described elsewhere .
DNA Sequencing
Sequencing of plasmids and RACE products was performed using the ABI PRISM TM Dye Terminator Cycle Sequencing Ready Reaction Kit (PE Biosystems) and following manufacturer's recommended conditions. Reactions were run on an ABI 377 automatic sequencer (PE Biosystems).
Cosmids q25 and q27 were sequenced by the Sanger Centre in Cambridge using shotgun and directed approaches. Subsequent analysis of q25 and q27 sequence was carried out via the United Kingdom MRC Human Genome Project Resource Centre's Nucleotide Identify X (NIX) front-end World Wide Web software-which includes Grail, Fex, Hexon, MZEF, Genemark, Genefinder, and Blast software-either searching EMBL, TREMBL, Swissprot, sequence-tagged-site, and expressed-sequence-tag databases or predicting gene features de novo, as appropriate. The DNA fragment in between q25 and q27 was isolated by PCR using primers q27F (GACCTTAAGACACACCATG) and q25R (GCTTATGGATATCCAGCAG), cloned in pBluescript and sequenced.
Rapid Amplification of cDNA ends (RACE)
RACE reactions were performed using Clontech's Placenta Marathon Ready cDNA kit, according to the manufacturer's conditions. Gene-specific primers for ZNF215 were: 5 RACE, Zn4 ATGAACTTCGGCA-GAAGGC and Zn2 GTCTCAGGAATGAAAGCC ( n e s t e d ) ; a n d 3 R A C E , Z n 7 C C T T C A -ACCGGAGCTCCTC and ME1 TGCATACTCGAGA-TAAGTCCTG (nested). Gene-specific primers for ZNF214 were: 5 RACE, 835R1 ATTTGAAGATTT-GAGCGCTGGGTA and 835R2 CCCTTACCACACT-CATCACAC (nested); 3 RACE, 833R1 GGGATT-CAGTCAGCGTTCACAT and 833R2 CAATGTGCT-AAGTGTGGTAAAGG (nested). PCR products were cloned in pUC18 using the Sureclone ligation kit (Promega).
Amplification of the ZNF215 Alternative Transcripts
cDNA was synthesized from 3 mg RNA using MMulV reverse transcriptase (Promega) and poly dT primer in 20 ml. 5 ml cDNA was used for PCR, using primers V3R (GACGGTAACTTTCATCAGAGC) and 215F1 (CAT-GACTCTGAGGCATCTCG) to amplify V3 and V1R and 215F1 to amplify V1,V4, and V5.
Green Fluorescent Protein Fusions
Full-length ZNF215V1 cDNA was generated by subcloning the KpnI-HindIII fragment from the 5 RACE product and the HindIII-EcoRV fragment containing part of exon 7 from q25, into the KpnI and EcoRV restriction site in pcDNA3. In order to clone the coding sequence in frame with GFP in pEGFP, ZNF215V1 was amplified using primers with KpnI and BamHI linkers GAGGTACCGCTATCTCAAAACCTCGAA (F) and CAGGATCCATGAGATTTTATCCAGCA (R) and was cloned in pEGFPC1.
Full-length ZNF214 cDNA was generated by subcloning the HaeIII-KpnI fragment from the 5 RACE product and the KpnI-AvrI fragment containing the zinc fingers isolated from q27 into the EcoRV-XbaI sites in pcDNA3. ZNF214 was amplified using primers with BamHI and XhoI linkers CAGGATCCGCAGTAA-CATTTGAAGATG (F) and GACTCGAGGTAAACT-TTGATTAAAGCTG (R) and was cloned in pEGFPC1.
Hep3b cells and cos-7 cells were plated at 10% density and were grown for 8 h on microscopy slides in sixwell plates. 2 mg plasmid DNA (ZNF214-pEGFPC1, ZNF215V1-pEGFPC1, and pEGFPC1 [control]) was transfected overnight in 1 ml serum-free medium and 10 ml lipofectin (GIBCO BRL). After transfection, the medium was refreshed and cells were grown for another 8 h. Then cells were fixed in 4% paraformaldehyde, were dehydrated in alcohol series, and were mounted in Vectashield (Vector Laboratories).
Determination of Genomic Imprinting
ZNF215.-Genomic DNA was amplified using primers 5PZ (GAACTGTTGGTGCTGGAAC) and 5P1 (TCTGGCACTTGATACTCTCT) RT-PCR was performed on RNA isolated from tissues of heterozygous individuals. cDNA was synthesized from 1 mg RNA using MMulV reverse transcriptase (promega) and the internal primer V1R (GTCTCAGGAATGAAAGCC) (V1) or V3R (GACGGTAACTTTCATCAGAGC) (V3) in 20 ml. 5 ml cDNA was used for PCR using primers V1R/ 5PZ or V3R/5PZ to amplify ZNF215V1 and ZNF215V3, respectively. A nested PCR was performed on both using primers 5PZ and 5PR (TGCAGGGCA-TATCTTCATCT) to get the same fragments for both variants.
The PCR products were analyzed on a 12.5% nondenaturing AA gel and run at 5ЊC 600V, 25 mA for 3 hours on a genephor system (Amersham Pharmacia Biotech).
ZNF214.-Genomic DNA was amplified using primers 214F1 (GCTTTTATCTCACCATGGG) and 214R1 (TCTAAGGACTGCCAAGGC) RT-PCR was performed on RNA isolated from tissues of heterozygous individuals. cDNA was synthesized from 1mg RNA using MMulV reverse transcriptase (promega) and the internal primer 214R2 (CCATTGAATCTCTCAGTAGG) in 20 ml. 5 ml cDNA was used for PCR using primers 214F2 (TGGAAATTCCTGGATTCTTC) and 214R2. (semi-)Nested PCR was performed using primers 214F2 and 214R1. Sequencing was performed using Cy5-labeled primers on an ALFexpress automated sequencer (Amersham Pharmacia Biotech).
Mutation Analysis
DNA was isolated from peripheral blood lymphocytes of 32 BWS patients and 11 hemihypertrophy patients (all non-UPD cases). The coding regions of ZNF214 and ZNF215 were amplified by PCR (primers available on request). PCR products analyzed by SSCP on 12.5% nondenaturing polyacrylamide gels (Amersham Pharmacia Biotech) ran at 5ЊC and 15ЊC, as described in GeneGel Excel protocols (Amersham Pharmacia Biotech). DNA was stained using the Silver staining kit (Amersham Pharmacia Biotech). PCR products presenting abberant conformers were reamplified from genomic DNA and were sequenced in both directions by the fluorescent dideoxy chain-termination method on an ABI 377 sequencer (PE Biosystems).
Results
Construction of a Cosmid Contig over the Breakpoints
It has previously been shown that BWSCR2 is located between D11S776 and HPX . By screening a YAC library with cosmid e2378 (D11S776) we isolated YAC A39D9 that, by FISH analysis, overlapped the two breakpoints (data not presented). Cosmids subcloned from the YAC A39D9 were fingerprinted to identify potential overlap with each other and with other cosmids in the database (see Methods). We constructed a contig of 150 kb ( fig. 1a ) and the integrity of this contig was checked by hybridization on extended DNA ( fig. 1c, d) . Rearrangements in patients CRO2 and WH5.1 define BWSCR2 and FISH analysis shows that the cosmid q27 spans the CRO2 breakpoint ( fig. 1b ). Southern blots of WH5.1 DNA probed with fragments
Figure 1
Localization of the breakpoints. a, Schematic map of chromosome 11p15. The three different breakpoint regions are indicated. The translocation breakpoint of the rhabdoid tumor Tm87-16 also maps within BWSCR1. The cosmid contig in BWSCR2 is shown, as well as the localization of the breakpoints. b, Cosmid q27 hybridized to chromosomes of patient CRO2. Signals are visible on the normal 11, the derivative 11 and the derivative 10, indicating that this cosmid spans the breakpoint. c, FISH on linearized DNA, performed with cosmids q25 (red), q27 (green) and u280 (green) d, FISH on linearized DNA performed with cosmids q25 (green), q27 (red), and u280 (green). e, EcoRI digests of DNA derived from WH5.1, his father (WH5.2), his mother (WH5.3), and reference patients, hybridized with a fragment derived from q25. Two aberrant bands are detected in WH5.1 and WH5.3, indicating that this 7-kb EcoRI fragment contains the breakpoint.
Figure 2
Schematic representation of the BWSCR2 region. The breakpoint WH5.1 could be localized to a 1138-bp TaqI fragment. The position of CRO2 is not precisely mapped and is thought to be located in the last 15 kb of q27. Cosmids q25 and q27 were completely sequenced, allowing precise mapping of the exons of ZNF214 and ZNF215 in this region. Exons 3-7, covering the coding part of ZNF215, are present in cosmid q25; alternative exons 8 and 9 are present in cosmid q27. Exons 2 and 3 of ZNF214 were found at the centromeric end of q27. Exon 1 maps outside q27, and its localization is not yet known. The coding regions of the genes are stained black, and the 3 UTRs and 5 UTRs are depicted in gray.
derived from q25 showed that the breakpoint mapped to a ∼7-kb EcoRI fragment ( fig. 1e ). Additional experiments refined this localization to a 1138-bp TaqI fragment (data not shown).
Zinc-Finger Genes Are Associated with BWSCR2
In a previous study (Hoovers et al. 1992) , we demonstrated that cosmid e2378, that contains D11S776, contains zinc-finger motifs. The presence of this cosmid in the contig that overlaps the breakpoints led us to search for other zinc-finger motifs in this region, using a degenerate oligo coding for the conserved C 2 H 2 -zincfinger linker sequence HTGEKPY. Positive signals were observed in e2378 and in overlapping cosmids, and in q25, q24, and cSRL7e1. The positive fragments were subcloned and sequenced, and zinc-finger motifs were detected. Subsequently, we identified these motifs as being derived from two zinc-finger genes, ZNF214 and ZNF215, respectively encoded in q27 and q25. These observations suggested there might be zinc-fingercoding genes disrupted by the breakpoints in patients CRO2 and WH5.1. We therefore sequenced cosmids q25 and q27 to determine whether this was the case.
Sequence Analysis
Cosmids q27 and q25 were completely sequenced by the Sanger Centre. The 686-bp gap between q25 and q27 subsequently was isolated by use of PCR (see Material and Methods) and also were sequenced, which led to a 73-kb continuous sequence. Separately, the zincfinger sequences generated from q27 and q25 were used to screen cDNA libraries and to carry out RACE to isolate cDNAs for both genes. Extensive computer analysis (see Methods) of the cosmids detected only the two zinc-finger genes-ZNF214 and ZNF215-and, among others, an EST (AA639668) mapping to the region.
Analysis of the complete sequences of the two cosmids and comparison to the cDNA sequences enabled us to show that ZNF214 is located at the proximal end of q27 and transcription is towards the telomere; ZNF215 is located towards the proximal end of q25 and is transcribed towards the centromere: ZNF214 and ZNF215 are therefore transcribed convergently. The exon 1 of ZNF214 is not contained in q27: exon 2 is at 371-517 and exon 3 at 1671-3920. Three ESTs were found that run until 4695 or 5046, and probably represent transcripts that use alternative polyadenylation sites. Similarly, exons 1 and 2 of ZNF215 are encoded outside of q25; exon 3 is at 32721-32143, exon 4 at 23241-23157, exon 5 at 21729-21597, exon 6 at 21266-21171, and exon 7 at 9123-6767.
EST AA639668 contains part of exon 7 of ZNF215 (9123-9031), and two novel exons: 8 (at 14997-14903 in q27) and 9 (at 2532-2205 in q27). The latter runs antisense of ZNF214 (fig. 2 ). This suggests that ZNF215 is alternatively spliced, and this was tested by RT-PCR experiments making use of (1) primers derived from exon 3 and exon 9 and (2) mRNA from fibroblasts and the hepatoma cell-line Hep3B (fig. 3 ). Sequence analysis of resulting products showed that an mRNA was produced that contained exons 3, 4, 5, 6, 7, and 9, but not exon 8 (V3 in fig. 2 ). Additional RT-PCR experiments
Figure 3
Alternative transcripts of ZNF215. a, RT-PCR performed on fibroblasts and Hep3b RNA, using primers derived from exon 9 and exon 3. An 831-bp fragment is produced, representing ZNF215V3. b, Tissue-specific expression of the ZNF215V4 and ZNF215V5 splice variants. Kidney, liver, and placenta express predominantly the ZNF215V1 RNA. The smaller variants, ZNF215V4 and ZNF215V5 are expressed in brain tissue. This was reproducible in three more brain samples and two more kidney samples (data not shown).
Figure 4
a, Schematic representation of the ZNF214 gene. The KRAB domain and the zinc-finger region are indicated. b, Schematic representation of the ZNF215V1 gene. The SCAN box, KRAB domain and the zinc-finger region are indicated also revealed the presence of two additional splice forms, V4 and V5, which lack exon 5 and exons 5 and 6, respectively (fig. 2) . These splice variants show a tissuespecific expression pattern ( fig. 3 ). In general, both ZNF214 and ZNF215V1 are widely expressed at very low levels by northern analyses. Expression is highest in the testis (data not shown). ZNF215V2-ZNF215V5 are not detectable on northern blots, but they can be amplified by RT-PCR from several fetal and adult tissues.
ZNF214 and ZNF215 Proteins
ZNF214 ( fig. 4a ) contains 12 zinc fingers-of which fingers 1, 2, and 4 lack a cysteine, whereas fingers 2 and 4, respectively, lack a leucine and a phenylalanine residue in the consensus finger sequence, C X 2 C X 3 F X 5 L X 2 H X 3 H. At the N-terminal ZNF214 contains a KRABA domain. ZNF215 (fig. 4b ) contains four zinc fingers, which are present in two pairs of two, with a small spacer in between. ZNF215 contains a KRABA domain; similarities to a KRABB domain; and, at the aminoterminal, a SCAN box. A nuclear localization signal, KKKR, was also present. In the variants represented by ZNF215V3 and EST AA639668 (V2), the alternative splicing in exon 7 leads to truncated proteins consisting of only the SCAN box and KRAB domain and excluding the zinc fingers. In the ZNF215V3 variant, lacking exon 8, the open reading frame continues coding for 98 ad-ditional amino acids. In variants ZNF215V4 and ZNF215V5, the alternative splicing causes a frameshift, allowing only the synthesis of the SCAN box.
Zinc-finger proteins that are involved in transcription regulation exert their function in the nucleus. If ZNF214 and ZNF215 were involved in transcriptional regulation, in the most general sense, we would expect them to be located in the nucleus. We tested this by fusing the V1 cDNA of ZNF215 and the full-length cDNA of ZNF214 to the green fluorescent protein (GFP) in p-EGFPC1. Transfection of these constructs to cos-7 or Hep3b cells showed that, after 24 h, both ZNF214 and ZNF215 are present in the nucleus. Transfection of the control construct, the empty pEGFPc1 vector, led to
Figure 5
Subcellular localization of ZNF214 and ZNF215 Hep3b cells transfected with the empty pEGFPC1 vector (a), the GFP-ZNF214 (b), and GFP-ZNF215 (c) fusion proteins. Staining of GFP alone is seen throughout the whole cell. ZNF214 and ZNF215 are transported to the nucleus and display a speckled pattern of staining. , preferential ex-M 1 P pression of the maternal allele; M, expression almost exclusively from the maternal allele; M 1/≈ P, roughly equal expression slightly favoring the maternal allele; ND, not done. staining throughout the whole cell ( fig. 5 ). We note a speckled pattern of staining in the nucleus, excluding the nucleoli, which might indicate that the proteins are present in specific nuclear bodies or domains.
Genomic Imprinting
The molecular etiology of BWS clearly involves imprinting and loss of imprinting control, but there is no a priori reason to suggest that genes at BWSCR2 need to be imprinted, although both translocations in this region are maternally inherited. Nevertheless, we tested ZNF215 and ZNF214 to determine whether this was the case. We screened DNA of 10 normal fetuses and their mothers for polymorphic sites in both genes.
An ArG change at position 355 was identified in ZNF215. Two fetuses were heterozygous for this polymorphism while their mothers were homozygous. RNA isolated from different tissues of these two fetuses was used to determine allelic expression patterns of variants ZNF215V1 and ZNF215V3. SSCP analysis of appropriate RT-PCR products of ZNF215V1 and ZNF215V3 ( fig. 6a, b, c, d) shows that the maternal allele of ZNF215V1 is preferentially expressed in liver, lung, kidney, and testis but also that, in the brain and heart, these alleles are nearly equally expressed. Interestingly, ZNF215V3 also is partially imprinted in lung, liver, and kidney but is completely imprinted in heart. In brain tissue, however, complete imprinting is seen in fetus 2, whereas, in fetus 1, both alleles are expressedindicating either that, at least in this tissue, individual variation exists or that imprinting may vary in different stages of development (developmental stages of the fetuses used are not known). A summary of the results is shown in table 1.
In ZNF214, we found a polymorphism at position 383 (TrG and TrA). Sequencing analysis of appropriate RT-PCR products of ZNF214 showed that both alleles are expressed at roughly equal intensities in heart, lung, brain, and liver, indicating that ZNF214 is not imprinted.
Figure 6
Genomic imprinting of ZNF215. a, Schematic overview of the primers used for amplification of ZNF214 and ZNF215V1 and ZNF215V3. RT indicates primers used for reverse transcription. b, SSCP of ZNF215 genomic and cDNA. Both fetuses (1f and 2f) are heterozygous, whereas their mothers (1m and 2m) are homozygous. SSCP analysis of ZNF215V1 cDNA derived from different tissues of 1f and 2f homozygous control samples.shows that both alleles are expressed, although the maternal allele is more abundantly expressed in all tissues except brain and heart. SSCP analysis of ZNF215V3 cDNA shows that expression is predominantly from the maternal allele in lung, liver, kidney, and brain of 1f. Expression is exclusively from the maternal allele in heart and brain of 2f. c, Sequence analysis of ZNF214 on genomic heterozygous DNA and RT-PCR products of ZNF214 derived from different tissues of 1f and 2f shows no indication for imprinting.
Figure 7
Variations in ZNF214 and ZNF215. a, Sequence analysis of ZNF214 in patient HH5, who has the R252C variant, and a control individual. b, Alignment of the twelve zinc fingers of ZNF214. The amino acids of the conserved zinc-finger consensus sequence are indicated. The variable sites are indicated with red circles. The R252C variant restores the first imperfect zinc-finger, and the R426H is in the seventh zinc-finger. c, Sequence analysis of ZNF215 in patient B34 and a control individual. d, SSCP pattern of fragment 8 of ZNF215 from patient B34, her father (B34F) and her mother (B34M). The variant is inherited from the mother.
Mutational Analysis
Only two chromosomal rearrangements define BWSCR2. If either or both of ZNF214 and ZNF215 do indeed play a role in BWS, then we might expect mutations to be found in these genes in at least a subset of cytologically unaltered BWS patients. To search for these, we set up an SSCP strategy to screen for mutations in both genes in 32 patients with BWS and 11 patients with isolated hemihypertrophy (all non-UPD cases). In ZNF214, we found a 754CrT change in 6 of 44 patient samples (2 from patients with BWS, 2 from patients with BWS with hemihypertrophy, and 2 from patients with isolated hemihypertrophy), compared to 2 of 205 control individuals (significant at ). This change re-P ! .01 sults in an arginine-to-cysteine conversion in the first finger and restores this normally imperfect finger ( fig.   7b ). In addition a 1277GrA change, leading to a R426H substitution in the seventh zinc-finger, was found in a single patient ( fig. 7b ). This alteration is inherited from the presumably unaffected father.
In ZNF215, a 988GrT transition was found in 1 patient with BWS ( fig. 7c, d) . This variant was also found in the mother of the patient and was not present in 48 control individuals. The transition changes a glycine to a tryptophan in a potential phosphorylation site (RKGS).
Discussion
In this study, we set out to test the hypothesis that there could be a gene(s) located at the BWSCR2 region that could contribute to the BWS phenotype. The two chro-mosomal rearrangements that define BWSCR2 both disrupt the zinc-finger gene ZNF215, thus meeting the first formal requirement for any gene's involvement in the etiology of BWS-that it must be disrupted by the rearrangements.
The breakpoints in BWSCR2 disrupt alternativespliced ZNF215 transcripts (ZNF215V2 and ZNF215V3). These transcripts encode a truncated protein lacking the zinc fingers but retaining the KRAB and SCAN box functional domains. KRAB domains are found in about one-third of all C 2 H 2 -class zinc fingers and transfection experiments have shown that it is able to repress transcription (Margolin et al. 1994; Witzgall et al. 1994) . The function of a SCAN box is still unknown but its a-helical structure suggests that it may serve as a dimerization domain (Williams et al. 1995) . It is an attractive but speculative hypothesis that, on the basis of their respective protein motifs, ZNF215V1 is a zinc-finger transcription factor and that ZNF215V2 and ZNF215V3 are regulatory proteins. The finding that both ZNF214 and ZNF215V1 proteins are transported to the nucleus, as determined by transfection studies using GFP fusion proteins, is compatible with such a role. Alternative-spliced transcripts encoding truncated proteins are also found in some other transcription factors-for example, some members of the HOX gene family, whose alternative transcripts encode proteins lacking the homeobox domain (La Rosa et al. 1988; Shen et al. 1991; Hong et al. 1995; Fujimoto et al. 1998) . The ZNF215V2 and ZNF215V3 alternativespliced transcripts are partially antisense of ZNF214, and it is possible that transcription of ZNF215V2 and ZNF215V3 may modulate levels of ZNF214 transcription or translation.
Although we found some alterations in ZNF214 and ZNF215 in patients, we do not have evidence for functional mutations in these genes. The incidence of the 252C allele in ZNF214 is significantly higher in BWS than in the unaffected population, but its involvement in these diseases cannot yet be considered proven. A more direct test of function will be required to prove a causal relationship. The significance of the single R426H variant in ZNF214 and the G330W variant in ZNF215 is unclear.
The finding that ZNF215V1 and ZNF215V3 are imprinted may be significant. Both BWSCR2 rearrangements are maternally derived suggesting these two patients will harbor an active but rearranged ZNF215 gene and a paternally derived, unrearranged, but predominantly inactive normal gene.
BWSCR2 appears to be associated with hemihypertrophy, unlike rearrangements of BWSCR1 or BWSCR3. The mouse models of BWS suggest involvement of CDKN1C and IGF2 but fail to account for the presence of hemihypertrophy. The cdkn1c null mouse develops some BWS features such as omphalocoele and other abdominal-wall defects, but no overgrowth (Zhang et al. 1997; Yan et al. 1997) . The Igf2 transgenic mouse shows gigantism and organomegaly (Sun et al. 1997) . Together, these mice account for a large proportion of BWS features, but not hemihypertrophy. It has been suggested that mosaic UPD causes the local hypertrophy, but chimaeric transgenic Igf2 mice do not show this and the translocations involving BWSCR2 are constitutional. It is possible that hypertrophy is the product of a local stochastic event (possibly IGF2 activation) that can be largely asymmetric (hemihypertrophy) or largely symmetric (organomegaly). Evidence for this hypothesis does not yet exist and will require a proper understanding of the functions of the ZNF214 and ZNF215 proteins.
